6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes
November 3-4, 2011
New York, NY
Thursday, November 3, 2011
8:00 am
Pre-activity audience polling via ARS
Richard T. Silver, MD, FACP
Session I: Myelodysplastic Syndromes
Chairs: John M. Bennett, MD, and
Alan F. List, MD
8:20 am
Program overview
John M. Bennett, MD, and Alan F. List, MD
8:25 am
New molecular targets in MDS and MPN
Nicholas C.P. Cross, MA, PHD, FRCPath
8:50 am
Risk-adaptive strategies for MDS management
John M. Bennett, MD
9:15 am
The 5q syndrome: Molecular targets of disease and therapy
Alan F. List, MD
9:40 am
Immune signature-guided immunodepletion therapy in MDS
Pearlie K. Epling-Burnett, PharmD, PhD
10:05 am
Coffee break
10:25 am
Positioning hypomethylating agents and "the pipeline ahead"
Gail J. Roboz, MD
10:50 am
Progress in replacing the stem cell: Allogeneic HSCT
Sergio A. Giralt, MD
11:15 am
Lunch
Session II: Chronic Myeloid Leukemia
Chairs: John Goldman, MD, FRCP and
Rudiger Hehlmann, MD, PhD
1:05 pm
Update on the biology of CML
John Goldman, MD, FRCP
1:35 pm
Current treatment of CML with imatinib, dasatinib, and nilotinib
Hagop M. Kantarjian, MD
2:05 pm
New drugs in the treatment of CML
Jorge Cortes, MD
2:35 pm
How should patients be monitored? Current usage of FISH, PCR, mutation analysis, and plasma OCT-1
Michael Deininger, MD
3:05 pm
Coffee break
3:25 pm
Current management of accelerated- and blast-phase disease
Rudiger Hehlmann, MD, PhD
4:00 pm
Current status of bone marrow transplantation in CML
Sergio A. Giralt, MD
4:30 pm
Abstract presentations and discussion
Vesna Najfeld, PhD,
Jerry L. Spivak, MD, FACP, and
Ruben A. Mesa, MD
Chromosomal and FISH study of 286 patients with primary myelofibrosis reveals cryptic abnormalities and identifies lesions associated with favorable prognosis and disease progression
V. Najfeld, et al, P-1
Leukocyte plugging and microthrombi in capillaries contribute to decreased brain blood flow in animal models of myeloproliferative neoplasms
T. Santisakultarm, et al, P-2
Incidence, risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation
K. Wong, et al, P-3
5:15 pm
Closing notes and post-activity ARS assessment
5:30 pm
Adjourn
Friday, November 4, 2011
8:15 am
Welcome and pre-activity ARS assessment
Session III: Myeloproliferative Neoplasms
Chairs: Jerry L. Spivak, MD, FACP and
Andrew Schafer, MD
8:30 am
Clonal evolution and the MPN stem cell hierarchy
Radek Skoda, MD
9:00 am
JAK/STAT signalling and the MPN phenotype
Anthony R. Green, PhD, FRCP, FRCPath
9:30 am
Targeting JAK2 V617F and the signaling pathways synergizing with it
Stefan Constantinescu, MD, PhD
10:00 am
Coffee break
10:15 am
The molecular basis of polycythemia vera
Jerry L. Spivak, MD, FACP
10:45 am
Secondary erythrocytosis
Josef T. Prchal, MD
11:15 am
Using novel MPN biomarkers wisely: Strategies for diagnosis and clinical trials
Heike L. Pahl, PhD
11:45 am
Drugs for polycythemia vera therapy in 2011: Balancing benefits and risks
Jean-Jacques Kiladjian, MD, PhD
12:15 pm
Lunch
Session IV: Myeloproliferative Neoplasms cont’d
Chairs: Richard T. Silver, MD, FACP and
Ross Levine, MD
1:15 pm
Therapeutic targets for reducing the thrombosis rate in the MPN
Tiziano Barbui, MD
1:45 pm
Clinical correlates of MPN mutations
Alessandro M. Vannucchi, MD
2:15 pm
The potential of drug combinations in MPN treatment
Ronald Hoffman, MD
2:45 pm
Update on the treatment of myeloproliferative diseases with current JAK2 inhibitors
Srdan Verstovsek, MD, PhD
3:15 pm
Coffee break
3:30 pm
Assessing symptoms and response in MPN patients – Lessons from current and future therapies
Ruben A. Mesa, MD
4:00 pm
Anemia responses in myelofibrosis: Role of IMiD's and other therapies
Animesh Pardanani, MBBS, PhD
4:30 pm
Treatment of early myelofibrosis with interferon alpha-2b
Richard T. Silver, MD, FACP
5:00 pm
Closing notes and post-activity ARS assessment
5:30 pm
Adjourn











